Share on StockTwits

Amedisys (NASDAQ:AMED) was upgraded by investment analysts at CRT Capital from a “sell” rating to a “fair value” rating in a note issued to investors on Friday, TheFlyOnTheWall.com reports.

Shares of Amedisys (NASDAQ:AMED) traded up 29.81% on Friday, hitting $17.46. 5,008,619 shares of the company’s stock traded hands. Amedisys has a 52 week low of $9.51 and a 52 week high of $18.70. The stock’s 50-day moving average is $14. and its 200-day moving average is $14.74. The company’s market cap is $572.9 million.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by $0.63. The company had revenue of $298.74 million for the quarter, compared to the consensus estimate of $301.89 million. During the same quarter in the previous year, the company posted $0.13 earnings per share. The company’s quarterly revenue was down 9.1% on a year-over-year basis. Analysts expect that Amedisys will post $0.03 EPS for the current fiscal year.

A number of other analysts have also recently weighed in on AMED. Analysts at Zacks reiterated a “neutral” rating on shares of Amedisys in a research note on Wednesday. They now have a $14.00 price target on the stock. Separately, analysts at Avondale Partners downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, June 2nd. Finally, analysts at Piper Jaffray cut their price target on shares of Amedisys from $13.00 to $12.00 in a research note on Monday, May 12th. Three analysts have rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. Amedisys presently has a consensus rating of “Hold” and an average target price of $11.00.

Amedisys, Inc (NASDAQ:AMED) is a health care company focused on bringing home the continuum of care.

The Fly On The Wall

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.